Alan Pestronk

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6698189/publications.pdf

Version: 2024-02-01

87 papers	6,420 citations	71102 41 h-index	69250 77 g-index
93 all docs	93 docs citations	93 times ranked	8841 citing authors

#	Article	IF	Citations
1	A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease. New England Journal of Medicine, 2010, 362, 1396-1406.	27.0	674
2	A phase I/IItrial of MYOâ€029 in adult subjects with muscular dystrophy. Annals of Neurology, 2008, 63, 561-571.	5.3	407
3	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	14.8	398
4	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
5	TREM2Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 449.	9.0	221
6	Immunosuppressive treatment in multifocal motor neuropathy. Annals of Neurology, 1991, 30, 397-401.	5.3	206
7	Clinical features of lateâ€onset Pompe disease: A prospective cohort study. Muscle and Nerve, 2008, 38, 1236-1245.	2.2	200
8	Effect of muscle disuse on acetylcholine receptors. Nature, 1976, 260, 352-353.	27.8	158
9	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
10	Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology, 2016, 87, 2123-2131.	1.1	129
11	The clinical correlates of high-titer IgG anti-GM1 antibodies. Annals of Neurology, 1994, 35, 234-237.	5.3	127
12	Acquired immune and inflammatory myopathies. Current Opinion in Rheumatology, 2011, 23, 595-604.	4.3	121
13	Multifocal motor neuropathy. Neurology, 1997, 49, 1289-1292.	1.1	120
14	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy With High-Dose Intermittent Intravenous Methylprednisolone. Archives of Neurology, 2005, 62, 249.	4.5	105
15	Childhood chronic inflammatory demyelinating neuropathies. Neurology, 1996, 47, 98-102.	1.1	104
16	Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis. Annals of Neurology, 1989, 25, 98-102.	5.3	97
17	Nerve conduction studies in amyotrophic lateral sclerosis. Muscle and Nerve, 1992, 15, 1111-1115.	2.2	97
18	The clinical and diagnostic role of antiâ€GM₁ antibody testing. Muscle and Nerve, 1994, 17, 100-104.	2.2	95

#	Article	IF	Citations
19	Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Annals of Neurology, 1994, 35, 142-150.	5.3	95
20	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Molecular Genetics and Metabolism, 2012, 107, 456-461.	1.1	93
21	Congenital Titinopathy: Comprehensive characterization and pathogenic insights. Annals of Neurology, 2018, 83, 1105-1124.	5.3	93
22	Myopathy with anti-HMGCR antibodies. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e124.	6.0	92
23	Inflammatory myopathies with mitochondrial pathology and protein aggregates. Journal of the Neurological Sciences, 2009, 278, 25-29.	0.6	91
24	Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1071-1081.	1.9	81
25	The Clinical Outcome Study for dysferlinopathy. Neurology: Genetics, 2016, 2, e89.	1.9	75
26	SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology, 2015, 85, 665-674.	1.1	74
27	Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Neuron, 2020, 106, 589-606.e6.	8.1	71
28	Defining SOD1 ALS natural history to guide therapeutic clinical trial design. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 99-105.	1.9	68
29	Measurement of junctional acetylcholine receptors in myasthenia gravis: Clinical correlates. Muscle and Nerve, 1985, 8, 245-251.	2.2	67
30	Chronic motor neuropathies: Diagnosis, therapy, and pathogenesis. Annals of Neurology, 1995, 37, 43-50.	5.3	67
31	Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle and Nerve, 2013, 48, 440-444.	2.2	65
32	Effect of botulinum toxin on trophic regulation of acetycholine receptors. Nature, 1976, 264, 787-789.	27.8	60
33	Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naÃ¯ve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscular Disorders, 2019, 29, 167-186.	0.6	59
34	Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Annals of Neurology, 1983, 14, 235-241.	5.3	58
35	Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscular Disorders, 2015, 25, 289-296.	0.6	56
36	Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle and Nerve, 2010, 42, 53-61.	2.2	53

#	Article	IF	Citations
37	Frequent atrophic groups with mixed-type myofibers is distinctive to motor neuron syndromes. Muscle and Nerve, 2007, 36, 107-110.	2.2	51
38	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
39	Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Current Opinion in Neurology, 2010, 23, 482-488.	3.6	47
40	Primary ?-sarcoglycan deficiency responsive to immunosuppression over three years. , 1998, 21, 1549-1553.		46
41	Membrane myopathy: Morphological similarities to duchenne muscular dystrophy. Muscle and Nerve, 1982, 5, 209-214.	2.2	45
42	<scp>MORC</scp>2 mutations cause axonal <scp>C</scp>harcotâ€“<scp>M</scp>arieâ€“<scp>T</scp>ooth disease with pyramidal signs. Annals of Neurology, 2016, 79, 419-427.	5.3	44
43	CANOMAD and other chronic ataxic neuropathies with disialosyl antibodies (CANDA). Journal of Neurology, 2018, 265, 1402-1409.	3.6	40
44	Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharide. Muscle and Nerve, 2003, 27, 188-195.	2.2	39
45	Cryptogenic smallâ€fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptorâ€3. Muscle and Nerve, 2020, 61, 512-515.	2.2	34
46	Dimethyl sulphoxide reduces anti-receptor antibody titres in experimental myasthenia gravis. Nature, 1980, 288, 733-734.	27.8	31
47	Brachio-cervical inflammatory myopathies: Clinical, immune, and myopathologic features. Arthritis and Rheumatism, 2006, 54, 1687-1696.	6.7	30
48	Mitochondrial pathology in immune and inflammatory myopathies. Current Opinion in Rheumatology, 2010, 22, 651-657.	4.3	30
49	Clinical and laboratory features of neuropathies with serum IgM binding to TSâ€HDS. Muscle and Nerve, 2012, 45, 866-872.	2.2	30
50	The pathophysiology of penicillamine-induced myasthenia gravis. Annals of Neurology, 1986, 20, 740-744.	5.3	27
51	Motor neuropathies and serum IgM binding to NS6S heparin disaccharide or GM1 ganglioside. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 726-730.	1.9	27
52	Nerve ultrasound identifies abnormalities in the posterior interosseous nerve in patients with proximal radial neuropathies. Muscle and Nerve, 2016, 53, 379-383.	2.2	27
53	Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide. Muscle and Nerve, 1982, 5, 79-84.	2.2	25
54	Autoantibodies to GM1 ganglioside: different reactivity to GM1-liposomes in amyotrophic lateral sclerosis and lower motor neuron disorders. Journal of the Neurological Sciences, 1991, 104, 209-214.	0.6	24

#	Article	IF	Citations
55	Immune myopathies with perimysial pathology. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e434.	6.0	24
56	Treatable gait disorder and polyneuropathy associated with high titer serum IgM binding to antigens that copurify with myelin-associated glycoprotein. Muscle and Nerve, 1994, 17, 1293-1300.	2.2	23
57	Inflammatory myopathy with cytochrome oxidase negative muscle fibers: Methotrexate treatment. , 1998, 21, 1724-1728.		21
58	Assessment of disease progression in dysferlinopathy. Neurology, 2019, 92, .	1.1	20
59	Autophagic vacuolar pathology in desminopathies. Neuromuscular Disorders, 2015, 25, 199-206.	0.6	19
60	Survival among children with â€œLethalâ€•congenital contracture syndrome 11 caused by novel mutations in the gliomedin gene (GLDN). Human Mutation, 2017, 38, 1477-1484.	2.5	19
61	Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1224-1226.	1.9	19
62	Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	3.7	18
63	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Annals of Neurology, 2021, 89, 967-978.	5.3	17
64	Regional Ischemic Immune Myopathy: A Paraneoplastic Dermatomyopathy. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1126-1133.	1.7	15
65	Polymyositis: Reduction of acetylcholine receptors in skeletal muscle. Muscle and Nerve, 1985, 8, 233-239.	2.2	12
66	Clinical and Laboratory Profiles of Idiopathic Small Fiber Neuropathy in Children: Case Series. Journal of Clinical Neuromuscular Disease, 2017, 19, 31-37.	0.7	12
67	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
68	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
69	Homozygous recessive MYH2 mutation mimicking dominant MYH2 associated myopathy. Neuromuscular Disorders, 2018, 28, 675-679.	0.6	10
70	Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology, 2022, 98, .	1.1	10
71	Inflammatory Demyelinating Neuropathies. Current Treatment Options in Neurology, 2011, 13, 131-142.	1.8	9
72	Sarcopenia, age, atrophy, and myopathy: Mitochondrial oxidative enzyme activities. Muscle and Nerve, 2017, 56, 122-128.	2.2	9

#	Article	IF	Citations
73	Prevalence of Axonal Sensory Neuropathy With IgM Binding to Trisulfated Heparin Disaccharide in Patients With Fibromyalgia. Journal of Clinical Neuromuscular Disease, 2019, 20, 103-110.	0.7	9
74	Chronic Graft Versus Host Myopathies: Noninflammatory, Multi-Tissue Pathology With Glycosylation Disorders. Journal of Neuropathology and Experimental Neurology, 2020, 79, 102-112.	1.7	9
75	Cardiac and pulmonary findings in dysferlinopathy: A 3â€year, longitudinal study. Muscle and Nerve, 2022, 65, 531-540.	2.2	9
76	Pathology Features of Immune and Inflammatory Myopathies, Including a Polymyositis Pattern, Relate Strongly to Serum Autoantibodies. Journal of Neuropathology and Experimental Neurology, 2021, 80, 812-820.	1.7	8
77	Randomized phase 2 study of <scp>ACE</scp>â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	2.2	8
78	Critical reexamination of the thymus immunization model of myasthenia gravis. Muscle and Nerve, 1980, 3, 293-297.	2.2	6
79	A Novel Therapy for Myasthenia Gravis by Reducing the Endocytosis of Acetylcholine Receptors. Annals of the New York Academy of Sciences, 1993, 681, 298-302.	3.8	6
80	Dystrophinopathy mimicking metabolic myopathies. Neuromuscular Disorders, 2015, 25, 653-657.	0.6	6
81	Cystinosis distal myopathy, novel clinical, pathological and genetic features. Neuromuscular Disorders, 2017, 27, 873-878.	0.6	5
82	Immune myopathy with large histiocyte-related myofiber necrosis. Neurology, 2019, 92, e1763-e1772.	1.1	5
83	Myelinated and unmyelinated endoneurial axon quantitation and clinical correlation. Muscle and Nerve, 2016, 53, 198-204.	2.2	4
84	Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology, 2022, 13, 828525.	2.4	4
85	Treatable, motorâ€sensory, axonal neuropathies with C5bâ€9 complement on endoneurial microvessels. Muscle and Nerve, 2021, 63, 506-515.	2.2	2
86	DMSO and immunity. Nature, 1981, 290, 432-432.	27.8	0
87	Autoantibody Testing in Peripheral Neuropathy. , 2014, , 51-67.		0